[8-K] Applied Therapeutics, Inc. Reports Material Event
Applied Therapeutics, Inc. disclosed that Nasdaq notified the company its closing bid price had been below the $1.00 minimum for the last 30 consecutive business days, triggering an initial compliance period. Nasdaq has now granted an additional 180-calendar-day extension to regain compliance with the $1.00 bid-price requirement, extending the deadline to February 2, 2026. In connection with the extension, the company鈥檚 listing will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 15, 2025. The Extension Notice does not immediately affect the listing, and the company says it will monitor the bid price and consider available options, including a reverse stock split, to attempt to regain compliance. If the bid price reaches at least $1.00 for 10 consecutive business days before the deadline, Nasdaq will confirm compliance; otherwise Nasdaq may initiate delisting procedures and the company could appeal.
Applied Therapeutics, Inc. ha comunicato che Nasdaq ha notificato che il prezzo di chiusura delle azioni 猫 stato inferiore a $1,00 per 30 giorni di mercato consecutivi, avviando cos矛 un periodo iniziale di conformit脿. Nasdaq ha concesso una proroga aggiuntiva di 180 giorni di calendario per rientrare nel requisito del prezzo minimo di $1,00, spostando la scadenza al 2 febbraio 2026. In relazione a questa estensione, la quotazione della societ脿 sar脿 trasferita dal Nasdaq Global Market al Nasdaq Capital Market, con effetto dal 15 agosto 2025. L鈥檃vviso di proroga non incide immediatamente sulla quotazione: la societ脿 monitorer脿 il prezzo e valuter脿 le opzioni disponibili, incluso un reverse stock split, per cercare di ristabilire la conformit脿. Se il prezzo raggiunger脿 almeno $1,00 per 10 giorni di negoziazione consecutivi prima della scadenza, Nasdaq confermer脿 la conformit脿; in caso contrario Nasdaq potr脿 avviare le procedure di esclusione dalla quotazione e la societ脿 potr脿 presentare ricorso.
Applied Therapeutics, Inc. inform贸 que Nasdaq notific贸 que su precio de cierre estuvo por debajo de $1.00 durante los 煤ltimos 30 d铆as h谩biles consecutivos, lo que activ贸 un periodo inicial de cumplimiento. Nasdaq ha concedido una pr贸rroga adicional de 180 d铆as calendario para volver a cumplir con el requisito del precio m铆nimo de $1.00, ampliando el plazo hasta el 2 de febrero de 2026. En relaci贸n con esta extensi贸n, la cotizaci贸n de la compa帽铆a se trasladar谩 del Nasdaq Global Market al Nasdaq Capital Market, con efecto a partir del 15 de agosto de 2025. El aviso de extensi贸n no afecta de inmediato la cotizaci贸n; la compa帽铆a vigilar谩 el precio y considerar谩 las opciones disponibles, incluido un reverse stock split, para intentar recuperar la conformidad. Si el precio alcanza al menos $1.00 durante 10 d铆as h谩biles consecutivos antes del plazo, Nasdaq confirmar谩 el cumplimiento; de lo contrario, Nasdaq podr铆a iniciar procedimientos de exclusi贸n y la compa帽铆a podr铆a apelar.
Applied Therapeutics, Inc.電� Nasdaq臧� 斓滉芳 30鞓侅梾鞚� 鞐办啀鞙茧 膦呹皜臧� $1.00 氙鸽鞚挫棃雼り碃 韱奠頃� 齑堦赴 攴滌爼 欷�靾� 旮瓣皠鞚� 鞁滌瀾霅橃棃鞚岇潉 瓿奠嫓頄堨姷雼堧嫟. Nasdaq電� $1.00 毵れ垬順戈皜 鞖旉贝鞚� 須岆车頃� 靾� 鞛堧弰搿� 於旉皜搿� 180鞚�(雼牓鞚�)鞚� 鞐办灔鞚� 項堨毄頃橃棳 毵堦皭 旮绊暅鞚� 2026雲� 2鞗� 2鞚�搿� 鞐办灔頄堨姷雼堧嫟. 鞚� 鞐办灔鞐� 霐半澕 須岇偓鞚� 靸侅灔鞚� 2025雲� 8鞗� 15鞚�攵�搿� Nasdaq Global Market鞐愳劀 Nasdaq Capital Market鞙茧 鞚挫爠霅� 鞓堨爼鞛呺媹雼�. 鞐办灔 韱奠電� 歃夓嫓 靸侅灔鞐� 鞓來枼鞚� 欤检 鞎婌溂氅�, 須岇偓電� 順戈皜毳� 歆�靻嶌爜鞙茧 氇媹韯半頃橁碃 攴滌爼 欷�靾橂ゼ 須岆车頃橁赴 鞙勴暣 鞐硲頃�(毽矂鞀� 鞀ろ攲毽�)鞚� 韽暔頃� 臧�電ロ暅 氚╈晥鞚� 瓴�韱犿暊 瓴冹澊霛缄碃 氚濏様鞀惦媹雼�. 旮绊暅 鞚挫爠鞐� 膦呹皜臧� 鞐办啀 10瓯半灅鞚� 霃欖晥 斓滌唽 $1.00鞐� 霃勲嫭頃橂┐ Nasdaq臧� 欷�靾� 靷嫟鞚� 頇曥澑頃橃毵�, 攴鸽爣歆� 鞎婌溂氅� Nasdaq臧� 靸侅灔韽愳 鞝堨皑毳� 臧滌嫓頃� 靾� 鞛堨溂氅� 須岇偓電� 鞚挫潣鞁犾箔頃� 靾� 鞛堨姷雼堧嫟.
Applied Therapeutics, Inc. a annonc茅 que le Nasdaq a inform茅 la soci茅t茅 que son cours de cl么ture avait 茅t茅 inf茅rieur 脿 1,00 $ pendant 30 jours de bourse cons茅cutifs, d茅clenchant une p茅riode initiale de conformit茅. Le Nasdaq a accord茅 une prolongation suppl茅mentaire de 180 jours calendaires pour retrouver le respect de l'exigence d'un cours d'offre d'au moins 1,00 $, repoussant la date limite au 2 f茅vrier 2026. Dans le cadre de cette extension, la cotation de la soci茅t茅 sera transf茅r茅e du Nasdaq Global Market au Nasdaq Capital Market, 脿 compter du 15 ao没t 2025. L'avis de prolongation n'affecte pas imm茅diatement la cotation ; la soci茅t茅 surveillera le cours et examinera les options disponibles, y compris un regroupement d'actions (reverse stock split), pour tenter de se conformer. Si le cours atteint au moins 1,00 $ pendant 10 jours de bourse cons茅cutifs avant la date limite, le Nasdaq confirmera la conformit茅 ; sinon, le Nasdaq pourra engager une proc茅dure de radiation et la soci茅t茅 pourra faire appel.
Applied Therapeutics, Inc. teilte mit, dass Nasdaq dem Unternehmen mitgeteilt hat, dass der Schlusskurs an 30 aufeinanderfolgenden Handelstagen unter $1,00 lag und damit eine erste Nachfrist ausgel枚st wurde. Nasdaq hat nun eine zus盲tzliche Verl盲ngerung von 180 Kalendertagen gew盲hrt, um die Einhaltung der $1,00-Bietpreisanforderung wiederherzustellen, wodurch die Frist bis zum 2. Februar 2026 verl盲ngert wird. Im Zusammenhang mit dieser Verl盲ngerung wird die Notierung des Unternehmens ab dem 15. August 2025 vom Nasdaq Global Market zum Nasdaq Capital Market verlegt. Die Verl盲ngerungsmitteilung wirkt sich nicht sofort auf die Notierung aus; das Unternehmen wird den Kurs 眉berwachen und m枚gliche Ma脽nahmen pr眉fen, einschlie脽lich eines Reverse-Stock-Split, um die Compliance wiederherzustellen. Erreicht der Kurs vor Fristende an 10 aufeinanderfolgenden Handelstagen mindestens $1,00, best盲tigt Nasdaq die Einhaltung; andernfalls kann Nasdaq Delisting-Verfahren einleiten und das Unternehmen dagegen Berufung einlegen.
- Nasdaq granted an additional 180-calendar-day extension to regain compliance, extending the cure period to February 2, 2026
- Listing remains on Nasdaq and the Extension Notice has no immediate effect on the trading of the Common Stock
- Closing bid price was below $1.00 for 30 consecutive business days, triggering the initial deficiency notice
- Listing will transfer from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 15, 2025
- Risk of delisting remains if the company does not regain compliance by February 2, 2026
Insights
TL;DR: Nasdaq gave APLT more time to meet the $1.00 bid-price rule; extension delays delisting but signals near-term marketability risk.
The extension to February 2, 2026 provides a meaningful runway to correct the bid-price deficiency without immediate delisting, preserving trading on Nasdaq. However, transfer to the Nasdaq Capital Market is a class downgrade in listing tier and may reduce visibility and liquidity. The explicit 10-consecutive-business-day cure condition means the company needs sustained price improvement rather than transient upticks. Management鈥檚 mention of a reverse split is a typical remedial option, but such corporate actions can have mixed investor reception and require careful timing and communication.
TL;DR: The Nasdaq extension buys governance time but highlights continued market-price pressure and potential impacts on capital access.
The formal notice documents a regulatory deficiency that the board and management must address through investor relations, potential capital strategy adjustments, or structural actions such as a reverse split. The transfer to the Nasdaq Capital Market is procedural but sends a public signal about the company鈥檚 market standing. The company retains procedural rights, including the right to appeal any future delisting determination, which preserves governance options while the firm seeks to restore compliance.
Applied Therapeutics, Inc. ha comunicato che Nasdaq ha notificato che il prezzo di chiusura delle azioni 猫 stato inferiore a $1,00 per 30 giorni di mercato consecutivi, avviando cos矛 un periodo iniziale di conformit脿. Nasdaq ha concesso una proroga aggiuntiva di 180 giorni di calendario per rientrare nel requisito del prezzo minimo di $1,00, spostando la scadenza al 2 febbraio 2026. In relazione a questa estensione, la quotazione della societ脿 sar脿 trasferita dal Nasdaq Global Market al Nasdaq Capital Market, con effetto dal 15 agosto 2025. L鈥檃vviso di proroga non incide immediatamente sulla quotazione: la societ脿 monitorer脿 il prezzo e valuter脿 le opzioni disponibili, incluso un reverse stock split, per cercare di ristabilire la conformit脿. Se il prezzo raggiunger脿 almeno $1,00 per 10 giorni di negoziazione consecutivi prima della scadenza, Nasdaq confermer脿 la conformit脿; in caso contrario Nasdaq potr脿 avviare le procedure di esclusione dalla quotazione e la societ脿 potr脿 presentare ricorso.
Applied Therapeutics, Inc. inform贸 que Nasdaq notific贸 que su precio de cierre estuvo por debajo de $1.00 durante los 煤ltimos 30 d铆as h谩biles consecutivos, lo que activ贸 un periodo inicial de cumplimiento. Nasdaq ha concedido una pr贸rroga adicional de 180 d铆as calendario para volver a cumplir con el requisito del precio m铆nimo de $1.00, ampliando el plazo hasta el 2 de febrero de 2026. En relaci贸n con esta extensi贸n, la cotizaci贸n de la compa帽铆a se trasladar谩 del Nasdaq Global Market al Nasdaq Capital Market, con efecto a partir del 15 de agosto de 2025. El aviso de extensi贸n no afecta de inmediato la cotizaci贸n; la compa帽铆a vigilar谩 el precio y considerar谩 las opciones disponibles, incluido un reverse stock split, para intentar recuperar la conformidad. Si el precio alcanza al menos $1.00 durante 10 d铆as h谩biles consecutivos antes del plazo, Nasdaq confirmar谩 el cumplimiento; de lo contrario, Nasdaq podr铆a iniciar procedimientos de exclusi贸n y la compa帽铆a podr铆a apelar.
Applied Therapeutics, Inc.電� Nasdaq臧� 斓滉芳 30鞓侅梾鞚� 鞐办啀鞙茧 膦呹皜臧� $1.00 氙鸽鞚挫棃雼り碃 韱奠頃� 齑堦赴 攴滌爼 欷�靾� 旮瓣皠鞚� 鞁滌瀾霅橃棃鞚岇潉 瓿奠嫓頄堨姷雼堧嫟. Nasdaq電� $1.00 毵れ垬順戈皜 鞖旉贝鞚� 須岆车頃� 靾� 鞛堧弰搿� 於旉皜搿� 180鞚�(雼牓鞚�)鞚� 鞐办灔鞚� 項堨毄頃橃棳 毵堦皭 旮绊暅鞚� 2026雲� 2鞗� 2鞚�搿� 鞐办灔頄堨姷雼堧嫟. 鞚� 鞐办灔鞐� 霐半澕 須岇偓鞚� 靸侅灔鞚� 2025雲� 8鞗� 15鞚�攵�搿� Nasdaq Global Market鞐愳劀 Nasdaq Capital Market鞙茧 鞚挫爠霅� 鞓堨爼鞛呺媹雼�. 鞐办灔 韱奠電� 歃夓嫓 靸侅灔鞐� 鞓來枼鞚� 欤检 鞎婌溂氅�, 須岇偓電� 順戈皜毳� 歆�靻嶌爜鞙茧 氇媹韯半頃橁碃 攴滌爼 欷�靾橂ゼ 須岆车頃橁赴 鞙勴暣 鞐硲頃�(毽矂鞀� 鞀ろ攲毽�)鞚� 韽暔頃� 臧�電ロ暅 氚╈晥鞚� 瓴�韱犿暊 瓴冹澊霛缄碃 氚濏様鞀惦媹雼�. 旮绊暅 鞚挫爠鞐� 膦呹皜臧� 鞐办啀 10瓯半灅鞚� 霃欖晥 斓滌唽 $1.00鞐� 霃勲嫭頃橂┐ Nasdaq臧� 欷�靾� 靷嫟鞚� 頇曥澑頃橃毵�, 攴鸽爣歆� 鞎婌溂氅� Nasdaq臧� 靸侅灔韽愳 鞝堨皑毳� 臧滌嫓頃� 靾� 鞛堨溂氅� 須岇偓電� 鞚挫潣鞁犾箔頃� 靾� 鞛堨姷雼堧嫟.
Applied Therapeutics, Inc. a annonc茅 que le Nasdaq a inform茅 la soci茅t茅 que son cours de cl么ture avait 茅t茅 inf茅rieur 脿 1,00 $ pendant 30 jours de bourse cons茅cutifs, d茅clenchant une p茅riode initiale de conformit茅. Le Nasdaq a accord茅 une prolongation suppl茅mentaire de 180 jours calendaires pour retrouver le respect de l'exigence d'un cours d'offre d'au moins 1,00 $, repoussant la date limite au 2 f茅vrier 2026. Dans le cadre de cette extension, la cotation de la soci茅t茅 sera transf茅r茅e du Nasdaq Global Market au Nasdaq Capital Market, 脿 compter du 15 ao没t 2025. L'avis de prolongation n'affecte pas imm茅diatement la cotation ; la soci茅t茅 surveillera le cours et examinera les options disponibles, y compris un regroupement d'actions (reverse stock split), pour tenter de se conformer. Si le cours atteint au moins 1,00 $ pendant 10 jours de bourse cons茅cutifs avant la date limite, le Nasdaq confirmera la conformit茅 ; sinon, le Nasdaq pourra engager une proc茅dure de radiation et la soci茅t茅 pourra faire appel.
Applied Therapeutics, Inc. teilte mit, dass Nasdaq dem Unternehmen mitgeteilt hat, dass der Schlusskurs an 30 aufeinanderfolgenden Handelstagen unter $1,00 lag und damit eine erste Nachfrist ausgel枚st wurde. Nasdaq hat nun eine zus盲tzliche Verl盲ngerung von 180 Kalendertagen gew盲hrt, um die Einhaltung der $1,00-Bietpreisanforderung wiederherzustellen, wodurch die Frist bis zum 2. Februar 2026 verl盲ngert wird. Im Zusammenhang mit dieser Verl盲ngerung wird die Notierung des Unternehmens ab dem 15. August 2025 vom Nasdaq Global Market zum Nasdaq Capital Market verlegt. Die Verl盲ngerungsmitteilung wirkt sich nicht sofort auf die Notierung aus; das Unternehmen wird den Kurs 眉berwachen und m枚gliche Ma脽nahmen pr眉fen, einschlie脽lich eines Reverse-Stock-Split, um die Compliance wiederherzustellen. Erreicht der Kurs vor Fristende an 10 aufeinanderfolgenden Handelstagen mindestens $1,00, best盲tigt Nasdaq die Einhaltung; andernfalls kann Nasdaq Delisting-Verfahren einleiten und das Unternehmen dagegen Berufung einlegen.
FAQ
What did Applied Therapeutics (APLT) disclose about Nasdaq listing compliance?
What is the deadline for APLT to regain compliance with Nasdaq's bid-price requirement?
Will APLT be delisted immediately from Nasdaq?
What happens if APLT's stock price meets the requirement before the deadline?
What remedial actions did the company say it may consider?
